Hemitruncus arteriosus, anomalous origin of a pulmonary artery from the aorta, is a rare congenital heart disease frequently accompanied by other cardiovascular anomalies. In this case report, we present an exceedingly rare case of hemitruncus arteriosus in an 18-year-old male patient presenting with cyanosis and chest pain. Echocardiography raised a suspicion for aorto-pulmonary window; this was confirmed on cardiac computed tomography angiography. A magnetic resonance imaging study was performed for functional assessment. The resulting diagnosis was hemitruncus arteriosus with aberrant origin of the right coronary artery from the right pulmonary artery and unilateral absence of a pulmonary artery.

Hemitruncus arteriosus, anomalous origin of a pulmonary artery from the aorta, is a rare congenital heart disease frequently accompanied by other cardiovascular anomalies. In this case report, we present an exceedingly rare case of hemitruncus arteriosus in an 18-year-old male patient presenting with cyanosis and chest pain. Echocardiography raised a suspicion for aorto-pulmonary window; this was confirmed on cardiac computed tomography angiography. A magnetic resonance imaging study was performed for functional assessment. The resulting diagnosis was hemitruncus arteriosus with aberrant origin of the right coronary artery from the right pulmonary artery and unilateral absence of a pulmonary artery.

Hemitruncus arteriosus, anomalous origin of a pulmonary artery from the aorta, is a rare congenital heart disease frequently accompanied by other cardiovascular anomalies. In this case report, we present an exceedingly rare case of hemitruncus arteriosus in an 18-year-old male patient presenting with cyanosis and chest pain. Echocardiography raised a suspicion for aorto-pulmonary window; this was confirmed on cardiac computed tomography angiography. A magnetic resonance imaging study was performed for functional assessment. The resulting diagnosis was hemitruncus arteriosus with aberrant origin of the right coronary artery from the right pulmonary artery and unilateral absence of a pulmonary artery.

Hemitruncus arteriosus, anomalous origin of a pulmonary artery from the aorta, is a rare congenital heart disease frequently accompanied by other cardiovascular anomalies. In this case report, we present an exceedingly rare case of hemitruncus arteriosus in an 18-year-old male patient presenting with cyanosis and chest pain. Echocardiography raised a suspicion for aorto-pulmonary window; this was confirmed on cardiac computed tomography angiography. A magnetic resonance imaging study was performed for functional assessment. The resulting diagnosis was hemitruncus arteriosus with aberrant origin of the right coronary artery from the right pulmonary artery and unilateral absence of a pulmonary artery.

Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumour of uncertain differentiation and low metastatic potential, which occurs predominantly in children and young adults. It occurs mostly within the extremities, trunk, head and neck. We report the case of a 32-year-old female that was operated in our hospital in 2016 and twice in 2017. The patient had headaches and neck pain initially in 2016. We discuss the radiographic and histologic features initially found and the findings that ultimately led to the diagnosis of AFH. The patient had a past history of Hodgkin lymphoma.

OBJECTIVE: Prolonged use of nonsteroidal anti-inflammatory drugs is associated with severe side effects and toxicity. Therefore, we studied the anti-inflammatory role of Calcarea carbonica which had minimal toxicity at the low doses. METHODS: THP-1 human mononuclear cells were treated with C. carbonica to evaluate the 50% cytotoxicity concentration (CC) and 50% effective concentration (EC). Cell survival was evaluated in lipopolysaccharide-stimulated C. carbonica-treated cells. Nitric oxide (NO) and tumor necrosis factor-α (TNF-α) were measured to evaluate the anti-inflammatory activity of C. carbonica. Cyclooxygenase-2 (COX-2) protein expression was determined by Western blotting analysis, and the interaction of C. carbonica with the COX-2 protein was evaluated using molecular docking simulation. RESULTS: The CC and EC of C. carbonica were found to be 43.26 and 11.99 µg/mL, respectively. The cell survival assay showed a 1.192-fold (P = 0.0129), 1.443-fold (P = 0.0009) and 1.605-fold (P = 0.0004) increase in cell survival at 24, 48 and 72 h after initiating C. carbonica treatment, respectively. C. carbonica-treated cells showed a reduction in NO levels by 2.355 folds (P = 0.0001), 2.181 folds (P = 0.0001) and 2.071 folds (P = 0.0001) at 24, 48 and 72 h, respectively. The treated cells also showed a reduction in TNF-α levels by 1.395 folds (P = 0.0013), 1.541 folds (P = 0.0005) and 1.550 folds (P = 0.0005) at 24, 48 and 72 h, respectively. In addition, a 1.193-fold reduction (P = 0.0126) in COX-2 protein expression was found in C. carbonica-treated cells. The molecular docking showed interaction of C. carbonica with the phenylalanine 367 residue present in active site of Cox-2. CONCLUSION C. carbonica exhibited anti-inflammatory properties in lipopolysaccharide-stimulated cells by significantly reducing NO production and TNF-α level through downregulation of the COX-2 protein. This effect is probably mediated through interaction of C. carbonica with the phenylalanine 367 residue present in active site of Cox-2.